1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Intercam 1.5 mg/ml Oral Suspension for Dogs

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each ml contains:

Active substance:

Meloxicam 1.5 mg.

Excipients:

Qualitative composition of excipients and other constituents	**Quantitative composition if that information is essential for proper administration of the veterinary medicinal product**
Sodium benzoate	5 mg
Saccharin sodium	
Carmellose sodium	
Silica, colloidal anhydrous	
Citric acid monohydrate	
Sorbitol, liquid (non-crystallising	
Disodium phosphate dodecahydrate	
Honey flavour	
Purified water	

An off-white to yellowish coloured oral suspension.

3. CLINICAL INFORMATION

3.1 Target species

Dogs.

3.2 Indications for use for each target species

Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders.

3.3 Contraindications

Do not use in animals suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders.
Do not use in cases of hypersensitivity to the active substance or to any of the excipients.
Do not use in dogs less than 6 weeks of age.

3.4 Special warnings

None.

3.5 Special precautions for use

Special precautions for safe use in the target species:

Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as there is a potential risk of increased renal toxicity. This veterinary medicinal product for dogs should not be used in cats as it is not suitable for use in this species. In cats, Meloxicam 0.5 mg/ml oral suspension for cats should be used.

Special precautions to be taken by the person administering the veterinary medicinal product to animals.

Meloxicam and other non-steroidal anti-inflammatory drugs (NSAIDs) may cause hypersensitivity (allergic reactions). People with known hypersensitivity to NSAIDs should avoid contact with the veterinary medicinal product, including hand-to-mouth contact.
This veterinary medicinal product can cause eye irritation. In case of contact with the eyes, immediately rinse thoroughly with water. In case of accidental skin contact, wash thoroughly the affected area. Avoid dermal and oral exposure, including hand-to-mouth contact. Wash hands after use. Do not eat, drink or smoke while handling the veterinary medicinal product.
In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.

Avoid children gaining access to the solution and to the uneaten treated food. Close the bottle immediately after use, and do not leave a syringe containing solution in the sight and reach of children. Always replace the syringe and the bottle in the outer carton and store in a safe place out of the sight and reach of children.
Any uneaten medicated food must be disposed of immediately and the bowl washed thoroughly.
Meloxicam may have adverse effects on pregnancy and/or embryofoetal development. Avoid dermal and oral exposure including hand-to-mouth contact. Pregnant women or women attempting to conceive should wear impermeable gloves when administering the veterinary medicinal product, and when cleaning the contaminated food bowl.
Do not allow treated dogs to lick people especially children and pregnant women, throughout the duration of treatment.

Special precautions for the protection of the environment:

Not applicable.

3.6 Adverse events

Dogs:

Very rare (<1 animal / 10,000 animals treated, including isolated reports):	Appetite loss, vomiting, diarrhoea, blood in faeces, lethargy, renal failure, haemorrhagic diarrhoea, haematemesis, gastro-intestinal ulcer, elevated liver enzymes.

These side effects occur generally within the first treatment week and are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal.
If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See also the package leaflet for respective contact details.

3.7 Use during pregnancy, lactation or lay

The safety of the veterinary medicinal product has not been established during pregnancy and lactation.

Pregnancy and lactation:
Do not use in pregnant or lactating animals.

3.8 Interaction with other medicinal products and other forms of interaction

Other NSAIDs, diuretics, anticoagulants, aminoglycoside antibiotics and substances with high protein binding may compete for binding and thus lead to toxic effects. This veterinary medicinal product must not be administered in conjunction with other NSAIDs or glucocorticosteroids.
Pre-treatment with anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such veterinary medicinal products should be observed for at least 24 hours before commencement of treatment. The treatment-free period, however, should take into account the pharmacological properties of the veterinary medicinal products used previously.

3.9 Administration routes and dosage

Oral use.
To ensure a correct dosage, body weight should be determined as accurately as possible

Initial treatment is a single dose of 0.2 mg meloxicam/kg body weight on the first day. Treatment is to be continued once daily by oral administration (at 24-hour intervals) at a maintenance dose of 0.1 mg meloxicam/kg body weight.

For longer treatments, the dose of veterinary medicinal product can be adjusted to the lowest effective individual dose when the clinical response is observed (after 4 days or more), reflecting that the degree of pain and inflammation associated with chronic musculoskeletal disorders may vary over time.

Method of administration
Ensure accurate dosing.
Shake well before use.

To be administered orally either mixed with food or directly into the mouth using the dosing syringe supplied with the veterinary medicinal product.
Two syringes are provided with each bottle: one for small dogs (scaled until 20 kg) and one for large dogs (scaled until 60 kg).

The syringe fits onto the bottle and has a kg-body weight scale which corresponds to the maintenance dose (i.e. 0.1 mg meloxicam/kg body weight). Thus, for initiation of the therapy on the first day, twice the maintenance volume will be required.

As an alternative, it is possible to initiate treatment with meloxicam 5 mg/mL injectable solution for dogs.
The suspension can be given using the small measuring syringe (each scale corresponds to 1 kg body weight) for the dogs weighing less than 20 kg, or with the large measuring syringe (each scale corresponds to 5 kg body weight) for dogs weighing more than 20 kg.

A clinical response is normally seen within 3–4 days. Treatment should be discontinued after 10 days at the latest if no clinical improvement is apparent.

Avoid introduction of contamination during use.

3.10 Symptoms of overdose (and where applicable, emergency procedures, antidotes)

In the case of overdose, symptomatic treatment should be initiated.

3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance

Not applicable.

3.12 Withdrawal periods

Not applicable.

4. PHARMACOLOGICAL INFORMATION

4.1 ATCvet code: QM01AC06.

4.2 Pharmacodynamics

Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class which acts by inhibition of prostaglandin synthesis, thereby exerting anti-inflammatory, analgesic, anti-exudative and antipyretic effects. It reduces leukocyte infiltration into the inflamed tissue. To a minor extent it also inhibits collagen-induced thrombocyte aggregation. *In vitro* and *in vivo* studies demonstrated that meloxicam inhibits cyclooxygenase-2 (COX-2) to a greater extent than cyclooxygenase-1 (COX-1).

4.3 Pharmacokinetics

Absorption
Meloxicam is completely absorbed following oral administration and maximal plasma concentrations are obtained after approximately 7.5 hours. When the product is used according to the recommended dosage regime, steady state concentrations of meloxicam in plasma are reached on the second day of treatment.

Distribution
There is a linear relationship between the dose administered and plasma concentration observed in the therapeutic dose range. Approximately 97% of meloxicam is bound to plasma proteins. The volume of distribution is 0.3 l/kg.

Metabolism
Meloxicam is predominantly found in plasma and is also a major biliary excretion product whereas urine contains only traces of the parent compound. Meloxicam is metabolised to an alcohol, an acid derivative and to several polar metabolites. All major metabolites have been shown to be pharmacologically inactive.

Elimination
Meloxicam is eliminated with a half-life of 24 hours. Approximately 75% of the administered dose is eliminated via faeces and the remainder via urine.

5. PHARMACEUTICAL PARTICULARS

5.1 Major incompatibilities

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

5.2 Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 2 years.
Shelf life after first opening the immediate packaging: 6 months.

5.3 Special precautions for storage

This veterinary medicinal product does not require any special storage precautions.

5.4 Nature and composition of immediate packaging

42, 100 or 200 ml polyethylene terephthalate (PET) bottle with a HDPE tamper resistant child proof closure and an adapter for the syringe.
15 ml HDPE bottle with a HDPE tamper resistant child proof closure,
Each bottle is supplied with two measuring syringes: one for small dogs (up to 20 kg) and one for bigger dogs (up to 60 kg).

Not all pack sizes may be marketed.

5.5 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

6. NAME OF THE MARKETING AUTHORISATION HOLDER

C & H Generics Limited

7. MARKETING AUTHORISATION NUMBER(S)

VPA23184/002/001

8. DATE OF FIRST AUTHORISATION

9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS

10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS

Veterinary medicinal product subject to prescription.

Detailed information on this veterinary medicinal product is available in the Union Product Database (https://medicines.health.europa.eu/veterinary).